Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000899243-21-017373
Filing Date
2021-04-29
Accepted
2021-04-29 16:45:37
Documents
2
Period of Report
2021-04-29

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 4808
2 EX-24.1 DOCUMENT attachment1.htm EX-24.1 4693
  Complete submission text file 0000899243-21-017373.txt   10893
Mailing Address 1030 MASSACHUSETTS AVENUE SUITE 210 CAMBRIDGE MA 02138
Business Address 1030 MASSACHUSETTS AVENUE SUITE 210 CAMBRIDGE MA 02138 617-952-0555
Werewolf Therapeutics, Inc. (Issuer) CIK: 0001785530 (see all company filings)

EIN.: 823523180 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 1030 MASSACHUSETTS AVENUE SUITE 210 CAMBRIDGE MA 02138
Business Address
Asanuma Sakae (Reporting) CIK: 0001857822 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-40366 | Film No.: 21871489